MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

Gilead Sciences has exercised its option for an exclusive license for a preclinical bispecific program, triggering a $10 million payment to MacroGenics.

MacroGenics said it remains eligible to receive up to approximately $1.6 billion in additional development payments.